These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 12137667)

  • 1. Prostacyclin for pulmonary hypertension.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2002; (3):CD002994. PubMed ID: 12137667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostacyclin for pulmonary hypertension.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2003; (2):CD002994. PubMed ID: 12804447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin for pulmonary hypertension in adults.
    Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002994. PubMed ID: 15846646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
    Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
    Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Budev MM; Minai OA; Arroliga AC
    Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Cheng J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostanoids for pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostanoid therapy for pulmonary arterial hypertension.
    Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J; Gao Y; Deng B; Liu K
    Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst R
    Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.
    Hinderliter AL; Willis PW; Barst RJ; Rich S; Rubin LJ; Badesch DB; Groves BM; McGoon MD; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Koch G; Li S; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Long WA
    Circulation; 1997 Mar; 95(6):1479-86. PubMed ID: 9118516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ten years' experience in continuous intravenous epoprostenol therapy in severe pulmonary arterial hypertension].
    Pombo Jiménez M; Escribano Subías P; Tello de Meneses R; Gómez-Sánchez MA; Delgado Jiménez J; Dalmau González-Gallarza R; Lázaro Salvador M; Hernández Rodríguez I; Tascón Pérez J; Sáenz de la Calzada C
    Rev Esp Cardiol; 2003 Mar; 56(3):230-5. PubMed ID: 12622952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
    Barst RJ; Rubin LJ; McGoon MD; Caldwell EJ; Long WA; Levy PS
    Ann Intern Med; 1994 Sep; 121(6):409-15. PubMed ID: 8053614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.